Lung Adenocarcinoma

Showing 1 - 25 of 78

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Local and Peripheral Immune Responsive Landscape Induced by

Not yet recruiting
  • Lung Adenocarcinoma
  • Local Cryoablation
    • (no location specified)
    Oct 24, 2023

    Lung Adenocarcinoma Trial in Shijiazhuang (Tislelizumab,Platinum)

    Recruiting
    • Lung Adenocarcinoma
    • Shijiazhuang, Hebei, China
      The Fourth Hospital of Hebei Medical University (Hebei Tumor Hos
    Sep 24, 2023

    Lung Adenocarcinoma, Lymph Node Metastasis Trial in Shanghai (Selective Lymph Node Dissection)

    Recruiting
    • Lung Adenocarcinoma
    • Lymph Node Metastasis
    • Selective Lymph Node Dissection
    • Shanghai, Please Select, China
      Chaoqiang Deng
    Sep 4, 2023

    Lung Adenocarcinoma, Frozen Section, Sublobar Resection Trial in Shanghai (Sublobar Resection)

    Recruiting
    • Lung Adenocarcinoma
    • +2 more
    • Sublobar Resection
    • Shanghai, Shanghai, China
      Fudan University Cancer Center
    Sep 4, 2023

    Tumor Microenvironment

    Active, not recruiting
    • Lung Adenocarcinoma
      • (no location specified)
      Aug 5, 2023

      Novel Grading System of Resected Lung Adenocarcinoma

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • Whole Slide Image based Deep Learning Signature
      • Zunyi, Guizhou, China
      • +2 more
      Jun 27, 2023

      Segmentectomy Versus Lobectomy for Lung Adenocarcinoma = 2cm

      Recruiting
      • Lung Adenocarcinoma
      • Lobectomy with systemic lymph node dissection
      • Segmentectomy with systemic lymph node dissection
      • Yangpu, Shanghai, China
        Shanghai Pulmonary Hospital
      Apr 20, 2023

      Ovarian Cancer, Lung Adenocarcinoma Trial in United States (AZD5335, AZD5305)

      Not yet recruiting
      • Ovarian Cancer
      • Lung Adenocarcinoma
      • Duarte, California
      • +6 more
      Mar 21, 2023

      Intraoperative Frozen Section Pathology to Guide Surgical

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • Surgical resection
      • Shanghai, Shanghai, China
        Fudan University Cancer Center
      Mar 20, 2023

      Intraoperative Frozen Section Pathology to Guide Surgical

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • Surgical resection
      • Shanghai, Shanghai, China
        Fudan University Cancer Center
      Mar 31, 2023

      Intraoperative Frozen Section Pathology to Guide Surgical

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • Surgical resection
      • Shanghai, Shanghai, China
        Fudan University Cancer Center
      Mar 20, 2023

      Novel Grading System of Clinical Stage I Lung Adenocarcinoma

      Recruiting
      • Lung Adenocarcinoma
      • +2 more
      • PET/CT-based Radiomics Signature
      • Zunyi, Guizhou, China
      • +3 more
      Feb 12, 2023

      Segmentectomy, Lung Adenocarcinoma Trial (Segmentectomy)

      Not yet recruiting
      • Segmentectomy
      • Lung Adenocarcinoma
      • Segmentectomy
      • (no location specified)
      Jan 29, 2023

      Lung Adenocarcinoma Trial in Los Angeles (drug, procedure, other)

      Recruiting
      • Lung Adenocarcinoma
      • Los Angeles, California
        Yesenia Calzada
      Jan 27, 2023

      Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

      Not yet recruiting
      • Lung Adenocarcinoma
      • +3 more
      • Serplulimab and Bevacizumab injection
      • (no location specified)
      Dec 21, 2022

      Lung Adenocarcinoma, Ovarian Cancer, Peritoneal Carcinoma Trial in Philadelphia (huCART-meso cells)

      Recruiting
      • Lung Adenocarcinoma
      • +5 more
      • huCART-meso cells
      • Philadelphia, Pennsylvania
        University of Pennsylvania
      Dec 1, 2022

      Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer Trial in United States (PY159 Single agent dose level 1, PY159 Single

      Recruiting
      • Advanced Solid Tumor
      • +7 more
      • PY159 Single agent dose level 1
      • +17 more
      • San Francisco, California
      • +11 more
      Nov 3, 2022

      MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma Trial in Spain (Spartalizumab)

      Active, not recruiting
      • MSI-H Colorectal Cancer
      • +30 more
      • Badalona, Barcelona, Spain
      • +9 more
      Oct 24, 2022

      Lung Adenocarcinoma, Lung Tumors Trial run by the NCI (osimertinib, LAT)

      Completed
      • Lung Adenocarcinoma
      • Lung Neoplasms
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Oct 17, 2022

      Solid Tumors, Lung Adenocarcinoma, Osteosarcoma Trial in Tianjin (IBI188, GM-CSF, Cisplatin/Carboplatin)

      Terminated
      • Solid Tumors
      • +2 more
      • Tianjin, China
        Tianjin Medical University Cancer Institute and Hospital
      Oct 3, 2022

      I3LUNG: Integrative Science, Intelligent Data Platform for

      Not yet recruiting
      • Non Small Cell Lung Cancer
      • +3 more
        • Chicago, Illinois
        • +3 more
        Sep 13, 2022

        Lung Adenocarcinoma, Lung Large Cell Carcinoma, Resectable Lung Non-Small Cell Carcinoma Trial in Guam, Puerto Rico, United

        Recruiting
        • Lung Adenocarcinoma
        • +12 more
        • Birmingham, Alabama
        • +1612 more
        Aug 23, 2022

        Advanced Solid Tumor, Advanced Cancer, Advanced Carcinoma Trial (AMT-151)

        Not yet recruiting
        • Advanced Solid Tumor
        • +18 more
        • (no location specified)
        Aug 10, 2022

        ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy Trial in Changsha (Pembrolizumab Combined With Bevacizumab and

        Not yet recruiting
        • ALK Gene Mutation
        • +2 more
        • Pembrolizumab Combined With Bevacizumab and Chemotherapy
        • Changsha, Hunan, China
          Hunan Cancer Hospital
        Jul 14, 2022